title: Effects of methylprednisolone and aprotinin on phospholipase D activity of leukocytes in systemic inflammatory response induced by cardiopulmonary bypass.
abstract: OBJECTIVE
  To investigate the role of leukocyte phospholipase D (PLD) in systemic inflammatory response induced by cardiopulmonary bypass (CPB) and the effects of methylprednisolone and aprotinin on leukocyte PLD activity.
  
  
  METHODS
  Forty-two patients who received CPB open heart surgery were divided into 3 groups: methylprednisolone group, aprotinin group, and control group. Arterial blood (10 mL) was collected for assay of leukocyte PLD activity, myeloperoxidase (MPO) activity, and CD11b expression at 8 different time points in perioperative period. Plasma IL-6, IL-8, and C-reactive protein levels were also determined.
  
  
  RESULTS
  At the time point of ascending aorta declamped, leukocyte PLD activity for control group was (18 +/- 8) nmol choline . h-1 . mg-1, which was higher than that of pre-CPB (P < 0.01); the PLD activity for methylprednisolone group was (10 +/- 6) nmol choline . h-1 . mg-1 that was lower than control (P < 0.05), while it had no statistical difference compared with that of pre-CPB. In methylprednisolone group, PLD activity elevation was postponed to the time point of CPB stopped. There was no statistical difference in PLD activity between aprotinin group and control (P > 0.05). After administration of methylprednisolone or aprotinin, leukocyte CD11b expression, plasma IL-6, IL-8, C-reactive protein levels, and MPO activity decreased by different extent.
  
  
  CONCLUSIONS
  Leukocyte PLD activity was elevated significantly in systemic inflammatory response induced by CPB and methylprednisolone partially blunted the CPB-induced inflammatory response by inhibiting PLD activity.
authors.affiliation: Department of Cardiovascular Thoracic Surgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China.
authors.forename: M
authors.initials: M
authors.lastname: Wu
authors.forename: Y B
authors.initials: YB
authors.lastname: Lu
authors.forename: B
authors.initials: B
authors.lastname: Jiang
authors.forename: S W
authors.initials: SW
authors.lastname: Xu
authors.forename: R K
authors.initials: RK
authors.lastname: Chen
authors.forename: H L
authors.initials: HL
authors.lastname: Zhou
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D007611:Aprotinin / Q000627:therapeutic use*; D002315:Cardiopulmonary Bypass / Q000009:adverse effects*; D005260:Female; D006330:Heart Defects, Congenital / Q000201:enzymology / Q000601:surgery; D006349:Heart Valve Diseases / Q000201:enzymology / Q000601:surgery; D006801:Humans; D007962:Leukocytes / Q000201:enzymology; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use*; D008875:Middle Aged; D010739:Phospholipase D / Q000097:blood*; D018746:Systemic Inflammatory Response Syndrome / Q000188:drug therapy* / Q000201:enzymology / Q000209:etiology
chemical_list: D000893:Anti-Inflammatory Agents; D007611:Aprotinin; D010739:Phospholipase D; D008775:Methylprednisolone